Eris Lifesciences Ltd-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Eris Lifesciences Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014224
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:29
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:インド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Eris Lifesciences Ltd (Eris Lifesciences) is a pharmaceutical company that manufactures and commercializes generics products. The company through its divisions provides wide range of products including Maxum, Decal, Eritel H, Eritel CH 80 LS, Glimisave Max Forte 1, Mac Rabonik Plus, Vomisave Syrup, Nikomox CV Dry Syrup and others. Eris Lifesciences offer products in the therapeutic areas of cardiology, gastroenterology, orthopedics and diabetes. It offers products in the form of tablets, syrups and capsules. The company has its manufacturing facility located at Assam, India. Eris Lifesciences is headquartered in Ahmedabad, Gujarat, India.

Eris Lifesciences Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Eris Lifesciences Ltd, Medical Devices Deals, 2011 to YTD 2017 10
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Eris Lifesciences to Acquire Branded Generics Business from Strides Shasun for USD76.7 Million 12
Eris Lifesciences Acquires 40 Trademarks from Amay Pharma for USD5 Million 14
Private Equity 15
ChrysCapital Invests In Eris Lifesciences 15
Licensing Agreements 16
Aprica Healthcare Enters into Licensing Agreement with Eris Lifesciences 16
Equity Offering 17
Eris Lifesciences Raises USD270 Million in IPO 17
Acquisition 18
Eris Lifesciences Acquires UTH Healthcare for USD2 Million 18
Eris Lifesciences Acquires Additional 14% Stake in Kinedex Healthcare for USD2 Million 19
Eris Lifesciences Acquires 61.48% Stake in Kinedex Healthcare for USD9.2 Million 20
Eris Lifesciences Acquires Aprica Healthcare 21
ChrysCapital May Sell its Stake in Eris Lifesciences 22
Nrim May Acquire Additional Stake in Kinedex Healthcare 23
Nrim Invests in Kinedex Healthcare 24
Eris Lifesciences Ltd – Key Competitors 25
Eris Lifesciences Ltd – Key Employees 26
Eris Lifesciences Ltd – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Other Significant Developments 28
Aug 17, 2017: Eris Lifesciences Announces the Dhifting of the Registered Office of the Company 28
Appendix 29
Methodology 29
About GlobalData 29
Contact Us 29
Disclaimer 29

List of Tables
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Eris Lifesciences Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Eris Lifesciences Ltd, Medical Devices Deals, 2011 to YTD 2017 10
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Eris Lifesciences to Acquire Branded Generics Business from Strides Shasun for USD76.7 Million 12
Eris Lifesciences Acquires 40 Trademarks from Amay Pharma for USD5 Million 14
ChrysCapital Invests In Eris Lifesciences 15
Aprica Healthcare Enters into Licensing Agreement with Eris Lifesciences 16
Eris Lifesciences Raises USD270 Million in IPO 17
Eris Lifesciences Acquires UTH Healthcare for USD2 Million 18
Eris Lifesciences Acquires Additional 14% Stake in Kinedex Healthcare for USD2 Million 19
Eris Lifesciences Acquires 61.48% Stake in Kinedex Healthcare for USD9.2 Million 20
Eris Lifesciences Acquires Aprica Healthcare 21
ChrysCapital May Sell its Stake in Eris Lifesciences 22
Nrim May Acquire Additional Stake in Kinedex Healthcare 23
Nrim Invests in Kinedex Healthcare 24
Eris Lifesciences Ltd, Key Competitors 25
Eris Lifesciences Ltd, Key Employees 26
Eris Lifesciences Ltd, Subsidiaries 27

★海外企業調査レポート[Eris Lifesciences Ltd-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • The Walt Disney Company (DIS):企業の財務・戦略的SWOT分析
    The Walt Disney Company (DIS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Emzor Pharmaceutical Industries Ltd:企業の戦略的SWOT分析
    Emzor Pharmaceutical Industries Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • HTC Corporation:企業の戦略・SWOT・財務情報
    HTC Corporation - Strategy, SWOT and Corporate Finance Report Summary HTC Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Getronics NV:企業の戦略的SWOT分析
    Getronics NV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Bayer AG:企業の戦略・SWOT・財務情報
    Bayer AG - Strategy, SWOT and Corporate Finance Report Summary Bayer AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • PT. Millennium Pharmacon International TBK (SDPC):企業の財務・戦略的SWOT分析
    PT. Millennium Pharmacon International TBK (SDPC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key …
  • Noor Takaful:企業の戦略・SWOT・財務分析
    Noor Takaful - Strategy, SWOT and Corporate Finance Report Summary Noor Takaful - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Naver Corp (035420):企業の財務・戦略的SWOT分析
    Naver Corp (035420) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Petroleo Brasileiro SA:企業の戦略・SWOT・財務分析
    Petroleo Brasileiro SA - Strategy, SWOT and Corporate Finance Report Summary Petroleo Brasileiro SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • OyaGen Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary OyaGen Inc (OyaGen) is a biotechnology company that discovers, develops and commercializes novel pharmaceutical therapies. The company offers viral infectivity factor Dimerization Antagonist, Vif Interaction with APOBEC3G, Vif dependent polyubiquitination of APOBEC3G and APOBEC3G activators. …
  • Mitsui Fudosan Co., Ltd.:企業の戦略・SWOT・財務分析
    Mitsui Fudosan Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Mitsui Fudosan Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Snyder’s-Lance, Inc.:企業の戦略的SWOT分析
    Snyder's-Lance, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Recylex SA:企業の戦略・SWOT・財務分析
    Recylex SA - Strategy, SWOT and Corporate Finance Report Summary Recylex SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • PacWest Bancorp:企業の戦略・SWOT・財務情報
    PacWest Bancorp - Strategy, SWOT and Corporate Finance Report Summary PacWest Bancorp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Euro-Diagnostica AB-医療機器分野:企業M&A・提携分析
    Summary Euro-Diagnostica AB (Euro Diagnostica) is a medical device company that manufactures and markets purified reagents and antibodies. The company offers blood based solutions, developed to aid clinicians in diagnosis, prognosis, monitoring and treatment of autoimmune diseases. It offers product …
  • Cairn Energy Plc (CNE):企業の財務・戦略的SWOT分析
    Cairn Energy Plc (CNE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Dong-A Socio Holdings Co Ltd (000640):企業の財務・戦略的SWOT分析
    Dong-A Socio Holdings Co Ltd (000640) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Peakdale Molecular Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Peakdale Molecular Ltd (Peakdale), a subsidiary of Concept Life Sciences Ltd, is a company that offers drug discovery services. It service portfolio offers services including drug discovery, nucleoside chemistry, materials chemistry and research support services. Peakdale offers research sup …
  • Essar Power Ltd:企業の戦略的SWOT分析
    Essar Power Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Vascular Biogenics Ltd (VBLT):製薬・医療:M&Aディール及び事業提携情報
    Summary Vascular Biogenics Ltd (VBL) is a clinical biopharmaceutical company that discovers, develops and commercializes treatments for cancer. The company’s product pipeline includes VB-111. VBL’s product VB-111 is an anti-angiogenic agent for the specific inhibition of tumor vascular growth for ca …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆